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Abstract
Background: Previous studies have examined the association between polymorphisms in the coagulation factor VII
gene and the risk of coronary heart disease (CHD), but those studies have been inconclusive. This study was
conducted to assess the associations between these polymorphisms and CHD and evaluated the associations in
different ethnicities.
Methods: Literature-based searching was conducted to collect data and two methods, namely fixed-effects and
random-effects, were performed to pool the odds ratio (OR), together with the 95% confidence interval (CI).
Publication bias and between-study heterogeneity were also examined.
Results: Thirty-nine case-control studies of the three polymorphisms, R353Q (rs6046), HVR4 and -323Ins10
(rs36208070) in factor VII gene and CHD were enrolled in this meta-analysis, including 9,151 cases of CHD and
14,099 controls for R353Q, 2,863 cases and 2,727 controls for HVR4, and 2,862 cases and 4,240 controls for
-323Ins10. Significant association was only found in Asian population for R353Q (Q vs R), with pooled OR of 0.70
(95%CI: 0.55, 0.90). For the -323Ins10 polymorphism (10 vs 0), we found significant associations in both Asian and
European populations, with pooled ORs of 0.74(95%CI: 0.61, 0.88) and 0.63(95%CI: 0.53, 0.74), respectively. Marginal
significant association was found between HVR4 (H7 vs H5+H6) and CHD (OR = 0.88, 95% CI: 0.78, 1.00). There was
no evidence of publication bias, but between-study heterogeneity was found in the analyses.
Conclusions: The -323Ins10 polymorphism in factor VII gene is significantly associated with CHD in both Asian and
European populations, while R353Q polymorphism showed trend for association with CHD in Asians. Lack of
association was found for HVR4 polymorphism. Further studies are needed to confirm the association, especially for
-323Ins10 polymorphism.
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Background
Coronary heart disease (CHD) is the most common
cause of death in industrialized countries, and is rapidly
increasing in prevalence in developing countries such as
China and India. CHD is a multifactorial disease influ-
enced by both genetic and environmental determinants.
Coagulation activation plays a key role in thrombus
formation and variation and its factors have been asso-
ciated with the risk of CHD. Activation of the extrinsic
coagulation pathway plays a key role in hemostasis, and
thus factor VII contributes to the occurrence of throm-
botic events. High factor VII levels might disproportio-
nately enhance the coagulation cascade at the time of
plaque rupture, which could explain the apparently dif-
ferential association with fatal and nonfatal events.
There have been a number of reports that increased
factor VII activity is a risk factor for CHD [1-3], and it
is now well documented that certain polymorphisms in
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Factor VIIc, Factor VIIa and Factor VII antigen [1,4,5].
The R353Q (rs6046) and -323Ins10 polymorphisms
(rs36208070) have been associated with a 20% to 25%
reduction in plasma factor VII levels [6]. The R353Q
polymorphism alone can decrease plasma factor VII
levels [7]. Significant associations between R353Q and
-323Ins10 polymorphisms and FVII coagulant activity
(FVIIc) and antigen (FVIIAg) levels have also been
reported in Chinese population [8]. A recent genome
wide association study (GWAS) identified a SNP
(rs488703, in perfect LD with R353Q (rs6046)) in coagu-
lation factor VII gene significantly associated with
plasma levels of coagulation factor VII (p-value =
9.0*10
-259) [9]. Previous studies have examined the asso-
ciation of the three polymorphisms in the factor VII
gene, including R353Q polymorphism, intron 7 poly-
morphism (HVR4:H5, H6 and H7 alleles), and -323 0/10
bp insertion/deletion polymorphism (allele A1 corre-
sponds to the absence of the decamer (0) and allele A2
to its insertion 10), with the risk of CHD. But those stu-
dies have been inconclusive.
For the R353Q polymorphism, a single nucleotide
change determines the presence of glutamine (Q) or
arginine (R) at amino acid 353 of factor VII. The HVR4
polymorphism is a variable tandem repeat and consists
of three alleles: H5, H6 and H7. Some studies concluded
a protective role for the QQ and H7H7 genotypes in the
risk of myocardial infarction (MI) among patients with
CHD [10-12]. However, others failed to confirm such
results [13-16], including the Framingham Heart study
[17].
The -323Ins10, a 10-bp insertion in the promoter
region in linkage disequilibrium with R353Q [8,18], also
has been demonstrated to be functionally relevant; the
rare insertion allele of 10 bp, indeed, reduced the pro-
moter activity, as compared with the common allele, in
transfection experiments [19]. There have been several
reports on the association of cardiovascular disease with
this polymorphism (see Additional file 1). However, the
results have been conflicted.
Meta-analysis is a powerful tool for summarizing
results from different studies by producing a single esti-
mate of the major effect with enhanced precision. How-
ever, previous meta-analyses performed on studies for
factor VII (R353Q polymorphism) got different results
[20,21]. In this study, we conducted a meta-analysis to
examine the associations between the three polymorph-
isms in the factor VII gene and CHD, and evaluated the
associations in different ethnicities. We report an
updated meta-analysis for the R353Q polymorphism as
well as new pooled results for two polymorphisms
(HVR4 and -323Ins10).
Methods
Retrieval of published studies
We searched information from HuGE navigator (http://
www.hugenavigator.net/), and conducted a systematic
computerized literature search for papers published
before November 23, 2010. We searched PubMed,
Embase and two Chinese databases, Cqvip and CBM,
using various combinations of keywords, such as ‘coron-
ary heart disease’ or ‘coronary artery disease’ or ‘myocar-
dial infarction’ combined with ‘FVII’ or ‘coagulation
factor VII’ and ‘polymorphism’ and ‘genetic association’.
Manuscripts in languages of Chinese and English were
considered for review. The full texts of the retrieved
articles were read to decide whether information on the
topic of interest should be included. The reference lists
of the retrieved articles as well as those of review arti-
cles and previous meta-analyses on this topic were
searched to identify other studies that were not identi-
fied initially. Articles were included in the meta-analysis
if they examined the hypothesis that factor VII was
associated with CHD using a case-control design, and
had sufficient published data on the genotypes or allele
frequencies for determining an estimate of relative risk
(i.e. odds ratio (OR)) and a confidence interval (CI).
Data extraction
Two reviewers (Mo and Yang) independently examined
the retrieved articles using a data collection form, in
order to extract the information needed. From each
study the following data were abstracted: first author’s
last name, year of publication, country of the population
studied, the counts of persons with different genotypes
in cases and controls, the average age and the percen-
tage of men in case and control groups within each
study. Following data extraction, the reviewers checked
for any discordance until a consensus was reached.
Statistical analysis
The OR was used to compare contrasts of alleles or
genotypes between cases and controls. We computed
the genetic contrast of the mutant alleles (Q for R353Q,
H7 for HVR4 and insertion 10 for -323 0/10 bp inser-
tion/deletion polymorphism) versus the wildtype alleles
and contrasts of homozygous genotypes against the
others. In secondary analyses, we calculated specific ORs
according to the racial descent of subjects (separated
analyses for Caucasian, East Asian and other popula-
tion). We assessed the presence of between-study het-
erogeneity using the chi-square based Cochran’sQ
statistic. The inconsistency index I
2 (ranging from 0 to
100%) was also calculated, where higher values of the
index (I
2 > 50%) indicate the existence of heterogeneity
[22]. Publication bias was assessed with funnel plots and
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with their 95% CIs were estimated using the fixed-
effects or random-effects method. The random-effects
method [24], which in the presence of heterogeneity, is
more appropriate as it is prudent to take into account
an estimate of the between-study variance (I
2). Devia-
tions from the HWE were calculated by the chi-square
method. To examine specific subsets in these studies,
separate analyses were undertaken. This was achieved
by performing a sensitivity analysis, in which an indivi-
dual study was removed each time to assess the influ-
ence of each study. Likewise, a cumulative analysis was
performed according to the ascending date of publica-
tion to identify the influence of the first published study
on the subsequent publications and the evolution of the
combined estimate over time [25]. For all analyses per-
formed here, the statistical package Stata 10 (Stata Cor-
poration, College Station, Texas, USA) and the catmap
package developed using the R language (http://www.r-
project.org) were used. In all analyses statistically signifi-
cant results were declared as those with a P value <
0.05.
Results
We found 33 articles related to this topic on the HuGE
Navigator website. After the literature search and the
subsequent screening, we came up with 45 research
papers concerning the association of R353Q or
-323Ins10 or HVR4 polymorphism with CHD. One of
these papers contained information about distinct inde-
pendent populations and thus they are considered as
different studies which should be counted twice [26].
Other papers used the same case-control groups
[26-29], the same CHD patients [30,31], or reported dif-
ferent proportions according to different populations or
polymorphisms [32,33] of one study [26]. These studies
were used only once and participated in the sensitivity
analysis. A total of 39 studies were finally included in
this study (Figure 1). The detailed characteristics of each
study (Authors, year, and mean age, percentage of men
and genotype data in case control groups, etc.) were
summarized (see Additional file 1).
Meta-analysis for R353Q polymorphism
The 36 retrieved studies that were investigating the
association of R353Q polymorphism with CHD con-
tained information about 9,151 cases and 14,099 control
subjects (Table 1). For four of these 36 studies it is
apparent that deviations from hardy-Weinberg equili-
brium (HWE) could be detected. The pooled frequency
of the Q allele in CHD cases and controls was 12.2%
and 12.8% separately, and it was found to be 14.2% and
8.8% in the control subjects of Caucasian populations
and Asians, respectively.
Figure 2 shows that the combined ORs (random-effects
method) for the Q allele on CHD risk were 1.02 (95% CI:
0.94, 1.11) in European population and 0.70 (95%CI: 0.55,
0.90) in Asian population. There was a significant between-
study heterogeneity as indicated by the P value of the cor-
responding test (P = 0.01) and the value of the I
2 index (I
2
= 55.5%) for studies in Asian population. The sensitivity
analysis revealed the evidence for a single influential study
that was biasing the results. This study was that of Huang’s
research on the Chinese Ningxia Hui population [26]. If
this study was removed the analysis would produce an
overall estimate of 0.93 (95% CI: 0.86, 1.01). In the cumula-
tive meta-analysis we also observed the influential role of
the study by Huang et al. [26]. The overall estimation
became significant only after this study was included in the
cumulative meta-analysis. We assessed publication bias
using formal statistics, Begg’st e s ta n dE g g e r ’st e s t .T h e
results did not suggest publication bias in the studies
(Begg’s test, P = 0.212, and Egger’s test, P = 0.213)
Similar results were observed in a dominant model.
We did not examine a recessive model because the
 
45 research papers concerning 
the association for  F7 gene
polymorphisms and CHD 
81 potentially relevant
articles identified through
database searching 
33 potentially relevant articles
identified  the HuGE 
Navigator website 
110 potentially relevant articles after duplicates removed 
65 papers excluded for: 
Non-association studies 
Association studies for other diseases 
Not original studies (reviews, letters, etc.) 
39 studies were finally included: 
36 studies for R353Q 
12 studies for -323Ins10 
12 studies for HVR4 
6 studies were excluded: 
4 studies using the same case-controls
and 2 studies using the same patients
only include 1 study for each; 
2 studies reported a portion of 1 study   
Figure 1 Flow diagram for study selection process in the meta-
analysis of FVII gene polymorphisms and CHD.
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six studies equals to zero. Furthermore, significant
between-study heterogeneity was not found after exclud-
ing studies not in HWE, but this did not influence the
results significantly.
Meta-analysis for -323Ins10 polymorphism
Twelve studies investigated the association of -323Ins10
polymorphism with CHD, including 2,862 cases and
4,240 controls, were enrolled in this meta-analysis
(Table 1). For all the studies included, we found that the
control groups were all in HWE. The pooled frequency
of the A2 allele in CHD cases and controls was 14.7%
and 17.3%, respectively.
A significant association was observed between the A2
allele and the risk for CHD (Figure 3), yielding an overall
OR (fixed-effects method) of 0.73 (95% CI: 0.66, 0.82). A
dominant model also yielded a similar result, with a sig-
nificant overall OR of 0.69 (95% CI: 0.60, 0.78). By per-
forming subgroup analyses we found significant
associations in both Caucasian and Asian groups (Figure.
3). In the two contrasts considered (A2 allele versus A1
allele and A2A2+A1A2 versus A1A1), no significant het-
erogeneity was observed (P = 0.047 and 0.278, I
2 = 45.2
and 24.9%, respectively). The sensitivity analysis revealed
that there was not a single study influencing the results
significantly. After removing each study and calculating
the overall estimate and the 95% CI for the remaining
studies, the significance of the OR remained unchanged.
There was no publication bias in the studies.
Meta-analysis for HVR4 polymorphism
Twelve studies including 2,863 cases and 2,727 controls
were enrolled in this meta-analysis for the association
between HVR4 polymorphism and CHD (Table 1). The
control groups for all the studies included were in
HWE. The pooled frequency of the H7 allele was 35.3%
and 38.3% in CHD cases and controls, respectively.
The contrast of the H7 allele versus H5+H6 allele was
examined, marginal significant association was found
between the HVR4 polymorphism and the risk for CHD
(OR = 0.88, 95% CI: 0.78, 1.00, random-effects method)
(Figure 4). Performing subgroup analyses we found that
European studies indicated no significant association (OR
= 0.82, 95% CI: 0.55, 1.21). The combined OR for the stu-
dies involving Asian subjects was 0.87 (95% CI: 0.75,
1.01), as well as homogeneity of the results (I
2=4 7 . 0 % ,P
= 0.093) (Figure 4). There was a statistically significant
heterogeneity for the overall estimates as indicated by the
P value (equals to 0.007) of the corresponding test and I
2
= 57.4%. The sensitivity analysis revealed that there was
not a single study influencing the results significantly. In
the cumulative meta-analysis, we also observed strong
evidence suggesting that the first published study that
reported a significant association [11]. The overall esti-
mation became insignificant only after the study reported
by Batalla [34] was included in the cumulative meta-ana-
lysis. The results of Begg’st e s ta n dE g g e r ’st e s td i dn o t
suggest publication bias in the studies (Begg’st e s t ,P=
0.537, and Egger’s test, P = 0.635).
Discussion
A controversial relationship was reported between the
polymorphisms within the coagulation factor VII gene
and CHD in different populations, including previous
meta-analyses, led us to conduct the present study.
Wu et al.[20] conducted a meta-analysis and reported
that the combined RQ and QQ genotype of factor VII
Table 1 Meta-analysis of FVII gene polymorphisms and CHD
Polymorphisms Populations Number of studies Number of cases Number of controls MAF
%
OR(95%CI) P -value I
2
%
R353Q European 20 5720 10641 14.2 1.02(0.94-1.11) 0.623 11.4
(rs6046) East Asian 12 2652 2654 8.8 0.70(0.55-0.90) 0.005 55.5
Other 4 779 804 32.6 0.92(0.78-1.07) 0.280 0.0
Total 36 9151 14099 12.8 0.91(0.83-1.01) 0.069 51.2
-323Ins10 European 5 926 2426 13.0 0.74(0.61-0.88) 0.001 35.1
(rs36208070) East Asian 5 1620 1476 13.6 0.63(0.53-0.74) < 0.001 0.0
Other 2 316 338 35.8 1.10(0.84-1.43) 0.500 0.0
Total 12 2862 4240 17.3 0.73(0.66-0.82) < 0.001 45.2
HVR4 European 4 611 560 32.8 0.82(0.55-1.21) 0.317 76.6
East Asian 6 1793 1711 42.3 0.87(0.75-1.01) 0.059 47.0
Other 2 459 456 30.1 0.97(0.68-1.38) 0.844 65.6
Total 12 2863 2727 38.3 0.88(0.78-1.00) 0.059 57.4
MAF = Minor Allele Frequency (in control groups); OR = Odds Ratio; CI = Confidence Interval;
I
2: The inconsistency index for between-studies heterogeneity, where higher values of the index (I
2 > 50%) indicate the existence of heterogeneity.
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lar disease in 2,574 patients (OR 0.78, 95% CI 0.65 to
0.93), whereas the QQ genotype had offered more pro-
tection (OR 0.53, 95% CI 0.27 to 1.03). However, the
combined analyses result reported by Ye and coworkers
[21], among 24 available studies with a total of 7,444
patients and 12,110 control individuals, showed no sig-
nificant overall associations with CHD, yielding per-
allele relative risks (RR) of 0.97 (95% CI 0.91 to 1.04).
Our study showed the significant association between
R353Q polymorphism and CHD in Asian population.
The most noteworthy findings of this meta-analysis
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Figure 2 Meta-analysis for the relationship between R353Q polymorphism and CHD risk. The combined ORs along with their 95% CIs
were in the contrast of Q allele vs. R allele and estimated using the random-effects method.
Mo et al. BMC Medical Genetics 2011, 12:107
http://www.biomedcentral.com/1471-2350/12/107
Page 5 of 8were that the 353QQ+QR genotype and 353Q allele
consistently appeared to be significantly associated with
a reduced risk of CHD. Our result for the overall popu-
lation supported that of the recent meta-analysis con-
ducted by Ye and coworkers. We found five studies
reported after 2006, when Ye et al. conducted their
meta-analysis, and we reviewed these studies in our
study. In cumulative analysis we found significant over-
all associations between the R353Q polymorphism and
t h er i s kf o rC H Do n l ya f t e rt h es t u d yp u b l i s h e db y
Huang et al. [26] was included. Nevertheless, we still
failed to find significant associations for European and
other populations.
For the -323Ins10 polymorphism, the A2 allele was
observed to be a protective effect in both Asian and
European individuals, without publication bias and sig-
nificant heterogeneity. The A2A2+A2A1 genotype and
A2 allele consistently appeared to be significantly asso-
ciated with a reduced risk of CHD. For the HVR4 poly-
m o r p h i s m ,w ea l s of o u n dap r o t e c t i v ee f f e c ti nA s i a n
individuals, although the odds ratio failed to reach sta-
tistical significance in European population. The study
samples for the -323Ins10 and HVR4 polymorphism
were still small, further large case-control studies are
needed for these two polymorphisms.
According to our results, the association between F7
polymorphisms and CHD risk may be different in differ-
ent ethnicities. Significant association was only found in
East Asian population for the R353Q polymorphism in
our meta-analysis. We found no significant associations
in the Europeans, this result was consistent with the
study of CARDIoGRAM consortium (by corresponding
to authors). The -323Ins10 polymorphism was signifi-
cantly associated with CHD risk in both European and
East Asian populations. Lack of association was found
for HVR4 polymorphism both in European and East
Asian populations.
Several potential limitations of our study should be
noted. First, we should realize that the results might be
distorted by potential weakness and biases of genetic
association studies, such as genotyping error, phenotype
misclassification, population stratification, gene-gene or
gene-environment interactive effect, and selective
reporting biases [25,35]. Second, although no statistically
significant publication bias was found from Egger’st e s t ,
exclusion of unpublished studies may affect the validity
of the analysis. The eligible studies in our research were
mainly from Asia and Europe, data of other populations,
like African, was limited. Third, because we did not
have access to individual data, we could not control for
population stratification, nor could we adjust for vari-
ables in possible intermediate pathways.
The exact biological role of the particular polymorph-
ism remains to be determined. In theory, FVII contri-
bute to atherosclerosis through the generation of
thrombin and fibrin formation. Development of coagula-
tion in the vessel wall may result in production of
thrombin and activation of platelet, leading to the
release of various cytokines and the proliferation of
smooth muscle cells in the vessel wall. Thus, someone
with a lower FVIIc level may have less chance of devel-
oping CAD. Moreover, thrombin can have pro-inflam-
matory properties and pro-angiogenic activities.
Vascular tone, inflammation, blood viscosity, and angio-
genesis can play roles in initiating and maintaining an
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Figure 3 Meta-analysis for the relationship between -323Ins10
polymorphism and CHD risk. The combined ORs along with their
95% CIs were in the contrast of A2 allele vs. A1 allele and estimated
using the fixed-effects method.
 
NOTE: Weights are from random effects analysis
.
.
.
Overall  (I-squared = 57.4%, p = 0.007)
Salazar (2006)
Xu (2003)
Other
Subtotal  (I-squared = 65.6%, p = 0.088)
Huang H(Hui) (2009)
Zhang (2004)
Kang (2002)
Huang H(Han) (2009)
Sobti (2010)
East Asian
Shimokata (2002)
Iacoviello (1998)
ID
European
Subtotal  (I-squared = 76.6%, p = 0.005)
Girelli (2000)
Batalla (2001)
Subtotal  (I-squared = 47.0%, p = 0.093)
Feng (1999)
Study
0.88 (0.78, 1.00)
1.18 (0.84, 1.64)
0.66 (0.50, 0.87)
0.97 (0.68, 1.38)
0.81 (0.67, 0.97)
1.17 (0.85, 1.61)
1.15 (0.75, 1.77)
0.84 (0.71, 0.99)
0.82 (0.63, 1.05)
0.90 (0.66, 1.22)
0.66 (0.48, 0.90)
OR (95% CI)
0.82 (0.55, 1.21)
0.83 (0.58, 1.19)
1.34 (0.98, 1.84)
0.87 (0.75, 1.01)
0.52 (0.28, 0.98)
100.00
7.72
9.09
17.52
11.93
8.08
5.80
12.43
9.79
8.37
8.24
Weight
26.79
7.15
8.14
55.69
3.27
%
0.88 (0.78, 1.00)
1.18 (0.84, 1.64)
0.66 (0.50, 0.87)
0.97 (0.68, 1.38)
0.81 (0.67, 0.97)
1.17 (0.85, 1.61)
1.15 (0.75, 1.77)
0.84 (0.71, 0.99)
0.82 (0.63, 1.05)
0.90 (0.66, 1.22)
0.66 (0.48, 0.90)
OR (95% CI)
0.82 (0.55, 1.21)
0.83 (0.58, 1.19)
1.34 (0.98, 1.84)
0.87 (0.75, 1.01)
0.52 (0.28, 0.98)
100.00
7.72
9.09
17.52
11.93
8.08
5.80
12.43
9.79
8.37
8.24
Weight
26.79
7.15
8.14
55.69
3.27
%
  
1 .5 1 1.5
Figure 4 Meta-analysis for the relationship between HVR4
polymorphism and CHD risk. The combined ORs along with their
95% CIs were in the contrast of H7 allele vs. H5+H6 allele and
estimated using the random-effects method.
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Page 6 of 8elevation in BP and, therefore, are potential mechanisms
contributing to the association between FACTOR VII
and risk factors like smoking, diabetes, hypertension,
and mental stress. The FVII polymorphisms were
reported to be associated with decreased blood pressure
and a decreased risk of hypertension [36], suggesting
that these FVII variants might influence cardiovascular
risk through mechanisms other than thrombosis.
Further studies which aim to confirm the functional
variants should be needed. More studies are needed to
elucidate the complete range of the signal transduction
pathways that the variant is implicated in, and thus,
throw light in the underlying molecular mechanisms
that confer susceptibility to CHD. The particular poly-
morphism associated with CHD itself may not play a
functional role, but rather it may be located physically
close to the actual disease-predisposing gene.
In addition to the genetic markers described in this
analysis, many other polymorphisms in genes encoding
important biochemical or coagulation factors have been
studied. Those polymorphisms may be candidates for a
multivariate analysis. Future haplotypic approaches and
further haplotype-based meta-analyses will provide more
powerful and informative results than current single
genotype-based data.
Conclusions
The results of the present research suggested that
-323Ins10 polymorphism is significantly associated with
CHD. R353Q polymorphism showed trend for associa-
tion with CHD in Asian people but probably not in Eur-
opeans. Lack of association was found for HVR4
polymorphism. Further studies are needed to confirm
the association, especially for -323Ins10 polymorphisms.
Additional material
Additional file 1: Characteristics of the 39 eligible studies included
in meta-analysis. A table summarized the detailed characteristics of
each study included in the meta-analysis (First authors, published year,
and mean age, percentage of men and genotype data in case control
groups, etc.).
a 323 in the 5’ promoter region, (10-bp insertion in the
promoter region (5’FVII)), where allele A1 corresponds to the absence of
the decamer (0) and allele A2 to its insertion(10).
b NS = not specified, M
= matched.
c Study for Chinese Hui population.
d Study for Chinese Han
population
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